Introduction
Approximately 15-20% of cases of status epilepticus (SE) will become refractory. 1, 2 Seizures which have persisted over 120 min are considered refractory status epilepticus (RSE), which often requires intensive care for continuous intravenous antiepileptic drugs (AEDs), general anesthesia, and/or cardiorespiratory support 3 . Given its life-threatening nature, when conventional treatments fail, experimental pharmacologic and non-pharmacologic therapies are attempted. Most of the relevant clinical literature on treatment of RSE consists of case reports and series, with few controlled trials and systematic reviews. 3 Repetitive transcranial magnetic stimulation (rTMS) is a potential therapy for RSE. rTMS is a non-invasive technique where pulsed intracranial electrical current is induced by electromagnetic induction. In most subjects, a continuous train of low frequency (1 Hz) pulses results in cortical suppression, while trains of high frequency (5 Hz) pulses result in facilitation of cortical excitability. 4, 5 Several case reports describe low-frequency rTMS application in medication-refractory focal epilepsy or RSE in non-ICU patients, with mixed results. [6] [7] [8] rTMS is well-tolerated by patients with epilepsy, without reports of seizure exacerbation 9 and seizure suppression can be achieved by low frequency rTMS. 7 The efficacy and safety profile of antiepileptic rTMS in the ICU is poorly understood. Only one prior successful case of rTMS for RSE in the ICU has been reported. 10 Hypothetical concerns about interference with ICU electronic equipment may also limit clinical use and warrant further exploration. We present two patients with focal RSE managed in the ICU. In both cases, a clinical decision to treat the ongoing seizures with rTMS was made. rTMS was delivered by physicians experienced in the clinical application of rTMS. Informed consent was obtained. (Table 1) . On admission, he was on phenobarbital, phosphenytoin, pregabalin, and lamotrigine (Table 1) . Physical exam showed drowsiness and baseline mild left hemiparesis. Lumbar puncture was unremarkable. An MRI showed right parieto-occipital cortical thickening with mildly restricted diffusion, remote surgical resection and chronic right frontotemporal encephalomalacia.
After intravenous lorazepam, phosphenytoin and phenobarbital were ineffective, he was intubated and started on a midazolam infusion. Because of resulting bradycardia and persistent agitation, he was switched to propofol. While the number of seizures declined, the patient still experienced 30-40 electrographic seizures daily. These were characterized by rhythmic, sharp alpha frequency activity over the right frontotemporal region, with frequent bilateral spread, lasting up to several minutes each, without clinical correlate.
On day 4, due to risk of propofol infusion syndrome, pentobarbital infusion was initiated ( Table 1) . As pentobarbital was weaned, frequent electrographic seizures recurred. The ketogenic diet was initiated on day 6 but stopped on day 9 due to developing ileus. With attempted pentobarbital wean on day 16, his seizure frequency increased again (Fig. 1) , requiring a further moderate increase in his standing AEDs.
Finally, the clinical team decided to administer rTMS on day 21 over the right centrotemporal region. Neurologically, the patient was intubated and sedated. Prior to starting rTMS, the stimulating coil was discharged repeatedly at 100% machine output (MO) in mid-air to ensure absence of interference with the ICU monitoring equipment. Motor threshold (MT) could not be determined due to the patient's significant peripheral edema. Therefore, the team decided to stimulate at 70% MO.
11 Stimulation was applied with a figure-of-8 coil (Cool B56, Tonica, Denmark) centered over electrodes C4/T4 with handle oriented toward vertex. A single train at 1 Hz was applied for 20 min with the C4/T4 electrodes removed. The patient tolerated the stimulation uneventfully. ICU electronic equipment, including clinical computer console, vital signs monitor, ventilator, medication pump, feeding pump, bed, pneumatic boot machine, and EEG remained operational during neurostimulation.
In the 72 h prior to rTMS, a median of 22 electrographic seizures per day (range 5-22), and a median of 75 spike detections (range 57-86) were recorded. This decreased to 9 seizures per day (range 3-11) and 17 spike detections (range 15-355) in the 72 h following rTMS, which allowed pentobarbital and phenobarbital doses to be weaned and decreased, respectively (Fig. 1) . EEG background and mental status gradually improved and the patient was discharged to a rehabilitation center on day 47.
Patient 2
A 51 year old man with depression, sleep apnea, and focal epilepsy with dyscognitive features and secondary generalization presented with frequent focal seizures. Seizures originated from the left mid and posterior temporal region and were characterized by right arm and leg clonic movements lasting several minutes. His seizures continued despite a sensorimotor corticectomy in 1993, VNS placement in 1998, and numerous AED trials (Table 1) .
On presentation, he experienced 4-5 seizures daily (lasting 20-70 min/day). He was taking lamotrigine, levetiracetam, felbamate, and lorazepam (Table 1 ) and had received multiple doses of lorazepam and clonazepam without benefit before hospital arrival. Admission exam demonstrated increased right-sided hemiparesis and unsteady gait. Addition of lacosamide, high-dose lorazepam, higher-dose levetiracetam, and frequent VNS magnet activations were ineffective. He was transferred to the ICU for respiratory monitoring but was never intubated. As his seizures were clinically obvious, he was not continuously monitored on EEG.
On hospital day 9 there was a clinical decision to administer rTMS. The patient's VNS was deactivated prior to TMS start. A single 30 min 1 Hz rTMS train was delivered over the left sensorimotor cortex. Stimulation intensity was 100% hand MT as determined by visual inspection. The stimulation device and orientation was identical to that in case #1. The patient tolerated rTMS without complication. Again, the electronic equipment Prior to hospitalization, patient 1 had a temporo-parietal lobectomy in 1991, a vagus nerve stimulator placed in 1998, and had been tried on multiple antiepileptic medication therapies over the years, Including carbamazepine, valproic acide, tiagabine, levetiracetam, zonisamide, topiramate, felbamate, gabapentin, lacosamide, and rufinamide. Patient 2 had also previously received a sensorimotor corticectomy in 1993, and vagal nerve stimulator in 1993, and had been tried on multiple antiepileptic medications, including tranxene, phenobarbital, carbamazepine, valproic acid, gabapentin, and phenytoin prior to hospitalization. Abbreviations. bid (twice a day), tid (three times a day), qid (four times a day). d (days), mg (milligrams), kg (kilograms), h (hour), prn (as clinically indicated), MT (motor threshold), TMS (transcranial magnetic stimulation).
present, including clinical computer console, vital signs monitor, bed, and pneumatic boot machine were undisturbed during rTMS. Following rTMS, seizure frequency decreased from a total of 9 prolonged seizures in the 72 h prior to administration (20-50 min each), to a total of one prolonged focal motor seizure (45 min) occurring approximately 48 h after TMS administration. However, 72 h after rTMS, his seizures increased in frequency.
On day 12, VNS was again turned off in preparation for a second round of rTMS. However, because of seizure recurrence while the VNS was temporarily turned off and resulting alteration in consciousness, he was unable to consent for rTMS. During the last week of his hospital stay, his VNS settings (including output current and duty cycle) were increased. His seizure frequency and duration gradually returned to baseline. He was discharged after 22 days.
Discussion
Our two cases provide preliminary evidence of safety and efficacy of low frequency rTMS for management of focal RSE in the ICU. Our choice of protocol in these two cases of RSE in the ICU setting was based on our experience with epilepsia partialis continua in the outpatient setting. 7 In previous cases, lowfrequency 1 Hz stimulation has been applied at 90-100% MT over the seizure focus, for 20-30 min. In Patient 1, the clinical team spent significant time setting up equipment and testing whether TMS discharge would interfere with ICU electronics. Due to time constraints, the team was only able to apply 1 Hz TMS for 20 min. Furthermore, because the patient's significant peripheral edema did not allow for a motor threshold to be assessed, the stimulation intensity was applied at 70% MO. 11 In this patient, rTMS applied over the epileptogenic cortex was associated with decreased seizure frequency, allowing pentobarbital and phenobarbital to be weaned successfully. In the second patient, administration of rTMS temporarily decreased the frequency of seizure activity in the first 72 h after application. Notably, as in prior reports, rTMS did not exacerbate seizure frequency or induce secondary generalization in either patient. 7,13 rTMS also did not interfere with ICU equipment and monitoring. Previous commentaries have suggested that AEDs and anesthetics, by altering synaptic plasticity, could decrease the efficacy of neurostimulation. 7 Typically, electroconvulsive therapy (ECT) protocols used for RSE include decreased or withdrawn AEDs and anesthetics to allow a generalized convulsion. 12 This hypothesis has not been tested in the clinical setting with rTMS. Here, a reduction in seizure frequency following 1 Hz rTMS in a patient (case #1) who is intubated and sedated by a moderate-dose pentobarbital infusion as well as multiple AEDs, suggests that cortical plasticity can be effectively modulated by rTMS even under barbiturate anesthesia In a recent review and suggested treatment algorithm for super-refractory SE, rTMS was considered to be of low potential utility. 3 In contrast, our report and another recent case 10 suggest rTMS in RSE merits further exploration. New studies should investigate various rTMS stimulation parameters, safety issues, and bioengineering considerations in the ICU setting.
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Susan T. Herman MD has received support from Lundbeck, Inc; UCB Pharmaceuticals, and Fidelity Biosciences Research Institute. Dr. Alvaro Pascual-Leone serves on the scientific advisory boards for Nexstim, Neuronix, starlab Neuroscience, Neosync, and Novavision. Drs. Alvaro Pascual-Leone and Alexander Rotenberg are inventors on patents and patent applications related to noninvasive brain stimulation and real-time integration of TMS with EEG and fMRI. Dr. Alexander Rotenberg has served as a paid consultant for Sage Therapeutics Inc. The remaining authors have no disclosures to report. Fig. 1 . ICU course of Patient Number 1. On admission, the patient experienced between 40-50 seizures daily (blue line, daily seizure frequency). After the initiation of pentobarbital sedation on day 4, the patient's seizure frequency abated but did not completely discontinue. After developing ileus thought likely secondary to pentobarbital, there was an attempt to wean the pentobarbital on day 16 with resulting increased seizure frequency. His intravenous AEDS were further increased with modest improvement. On day 21, TMS was administered in the ICU over the seizure focus. The following day, the pentobarbital was successfully weaned with eventual cessation of seizures. The patient's EEG background (red line) and clinical status gradually improved.
